Since 2015, hypertension care has been contentious because of a single study: SPRINT (Systolic Blood Pressure Intervention Trial). This study, sponsored by the National Institutes of Health, was designed to answer a question debated for more than half a century: Is treatment of mild hypertension with medications warranted and, if so, to what blood pressure targets? A 2014 review of mild hypertension that I coauthored found little, if any, benefit to treatment. Therefore, SPRINT's results surprised myself and others in primary care, as did differing specialty interpretations about how—or whether—these results should influence hypertension management.